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Abstract
Recommendations for lung cancer screening present a tangible opportunity to integrate predictive blood-based assays with
radiographic imaging. This study compares performance of autoantibody markers from prior discovery in sample cohorts
from two CT screening trials. One-hundred eighty non-cancer and 6 prevalence and 44 incidence cancer cases detected in
the Mayo Lung Screening Trial were tested using a panel of six autoantibody markers to define a normal range and assign
cutoff values for class prediction. A cutoff for minimal specificity and best achievable sensitivity were applied to 256 samples
drawn annually for three years from 95 participants in the Kentucky Lung Screening Trial. Data revealed a discrepancy in
quantile distribution between the two apparently comparable sample sets, which skewed the assay’s dynamic range
towards specificity. This cutoff offered 43% specificity (102/237) in the control group and accurately classified 11/19 lung
cancer samples (58%), which included 4/5 cancers at time of radiographic detection (80%), and 50% of occult cancers up to
five years prior to diagnosis. An apparent ceiling in assay sensitivity is likely to limit the utility of this assay in a conventional
screening paradigm. Pre-analytical bias introduced by sample age, handling or storage remains a practical concern during
development, validation and implementation of autoantibody assays. This report does not draw conclusions about other
logical applications for autoantibody profiling in lung cancer diagnosis and management, nor its potential when combined
with other biomarkers that might improve overall predictive accuracy.
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Introduction
Results from the 10-year National Lung Screening Trial
(NLST) show low dose CT screening confers a survival benefit
in the at-risk population [1]. Although radiographic imaging is the
de-facto screening modality, circulating biomarkers have potential
to enhance early detection initiatives and further improve
outcomes [2–6]. Our group and others have been developing
autoantibody assays that could complement CT scanning in lung
cancer diagnosis and management [4–9]. It is now well established
that cancer patients produce autoantibodies to tumor proteins that
are mutated, misfolded, ectopically presented, over-expressed,
aberrantly degraded or anomalously glycosylated [4–13]. Assays
comprised of panels of robust and complementary markers
selected from an extensive repertoire of tumor-associated antibod-
ies are designed to compensate for tumor heterogeneity. Biological
amplification of low frequency cellular aberrancy makes autoan-
tibodies logical biomarkers for early detection and a prevailing
strategy for detecting occult malignancy [2–15]. Six markers from
prior discovery were analyzed in a comparative study using
samples from two independent CT screening studies. Integrity and
relative comparability of two screening sample cohorts from, each
with a high percentage of cancer samples drawn prior to
radiographic detection, offered a unique opportunity to test
principles, precepts, and dominant objectives of investigation to
date [7–9,16–18].
A panel of six autoantibody markers were used to assay samples
from the Mayo Clinic CT screening trial, to gather normal
distribution values, and generate a cutoff value that might be used
to improve efficiency of lung cancer screening. Established cutoff
values were applied to 285 samples from 95 participants of a
regional CT screening study in the 5th district of Kentucky
(Appalachia). The primary objective of the study was to determine
the ability of an autoantibody profile to detect lung cancers at the
time of or before CT scan. The uniformity of sample collection
and study entry criteria was an important standard for analysis
within and between the two screening sample cohorts. Class
prediction in sample sets comprised predominantly of occult lung
cancers (prior to radiographic detection) is a unique aspect of this
analysis. Accurate classification of stage I screening detected
cancers was a secondary metric.
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Materials and Methods
Ethics Statement
Samples were collected under protocols approved by accredited
Institutional Review Boards (Mayo Clinic IRB and University of
Kentucky IRB). All subjects provided written informed consent
prior to any research procedures. This research was approved by
respective IRBs and was conducted according to Institutional
Review Board regulations and oversight.
Mayo cohort
The Mayo Lung Screening Trial performed five annual CTs on
1520 subjects with a minimum 20 pack-year smoking history, age
50–75, and no other malignancy within five years of study entry
[16,17]. Cancer rates were 2.6% at 3 years rising to 4% at 5 years
of screening. A single blood sample was drawn at study entry. The
sample cohort was comprised of 180 non-cancer controls, six stage
I prevalence lung cancers, and 44 lung cancers diagnosed 12 to 60
months from blood draw [16,17].
Kentucky cohort
The Marty Driesler Lung Screening Project was a community-
based CT screening study that accrued 254 at risk subjects from
Eastern Kentucky between 2005 and 2008 [18]. Eligibility criteria
included age 55 to 75 years, 30 pack-years history of smoking, and
no other malignancy within five years of study entry. Cancer rate
was 2.6%. All subjects provided written informed consent prior to
any research procedures.
Since analysis of all available samples was cost prohibitive, a
sample set of two hundred fifty six samples from ninety-five
participants was constructed by an independent investigator and
analyzed in a blinded fashion. The test cohort of nineteen lung
cancer samples included five stage I screening detected lung
cancers (three prevalence, two incidence), and four lung cancers
diagnosed clinically one to five years after the last serial screening
CT and corresponding blood sample. One case of head and neck
cancer was diagnosed during the screening period, and six other
non-thoracic malignancies were diagnosed up to five years from
the last lung cancer screening CT. All cancer cases are
summarized in Table 1. One or more non-malignant pulmonary
nodules were noted in 56% of the study cohort. Dominant non-
malignant radiographic findings included emphysema, mediastinal
adenopathy and granulomatous disease.
Assay composition and procedures
Marker discovery, measurement and statistical analysis has been
described previously [7–9]. The marker panel was comprised of six
individual tumor-associated autoantibodies that offered robust
discrimination between cancer and noncancer samples in prior
analysis; these six also provided consistent performance as a
combined measure in a single assay based on receiver operating
characteristic area under the curve. T7-phage-expressed capture
proteins were derived from cDNA tumor libraries [7–9]. These
putative autoantibody markers corresponded to apurinic/apyr-
imidinic endonuclease-1 (APEX1), nucleolar and coiled-body
phosphoprotein 1 (NOLC1), splicing factor 3a (SF3A3), paxillin
(PXN), BAC clone R-580E16 (unknown protein product) and
mitochondrial 16S ribosomal RNA (MT-RNR2). [7,8 and
unpublished] All phage-expressed capture proteins were covalently
bound to Luminex microspheres for multiplex analysis using
commercially available protocols. Autoantibody levels were quan-
tified using biotinylated anti–human IgG and R-phycoerythrin–
labeled streptavidin. The mean absolute fluorescence to each
marker was calculated from triplicate measurements for each
sample. No-sample controls included in each run consistently
measured near zero.
A single absolute fluorescence value was generated for each
sample using the sum from individual markers. A cutoff value of
640, corresponding to the lower quartile (set specificity at 25%),
would be expected to maximize capacity for detecting cancer at
the earliest stages of disease while still providing an improved the
ratio of scans performed to cancers detected. That cutoff was
applied to class prediction in the Kentucky CT screening cohort.
Relevant points of data analysis included distribution in the at risk
population and comparability to the Mayo Clinic cohort,
consistency of annual measures from individual subjects, accurate
classification of cancer samples at the time of and prior to
radiographic detection.
Results
The additive sum of absolute fluorescence from six markers was
used as an intuitive measure of overall autoantibody reactivity to
provide a single value point for each sample, define distribution in
the at risk population, and assign cutoffs for cancer prediction in
an independent cohort. The median value across 180 non-cancer
samples from the Mayo Clinic sample cohort was 1126 fluorescent
units (FU), with 25%/75% quartile values of 640 and 2076 FU
respectively; there was one extreme outlier. A cutoff of 640
fluorescent units offered 88% sensitivity across fifty cancer samples
in the Mayo cohort, which included accurate classification of 6/6
established stage I cancers and 38/44 samples drawn one to five
years prior to radiographic appearance. By comparison the
median value across 237 non-cancer samples from the Kentucky
cohort was 726 fluorescent units (FU), with 25%/75% quartile
values of 461 and 1249 FU respectively, which is roughly one third
lower than measured in the Mayo Clinic sample cohort. A
contingency chart (table 2) shows class prediction in the Kentucky
cohort at the predetermined cutoff of 640 FU, and also bares the
effect of inflated cutoff values on sensitivity and specificity that
resulted from the discrepancy between the training and testing
cohorts. The cutoff of 640 FU accurately classified 102/237 non-
lung cancer samples (43%) and 11/19 cancer samples (58%),
which included 4/5 stage I lung cancers (80%), and 7/14 of occult
cancer samples (50%) one to five years prior to radiographic
appearance. Class prediction and temporal relationship of sample
draw to cancer diagnosis is summarized in table 1.
Squamous and adenocarcinoma histologies were both repre-
sented among the true positives; there was nothing uniquely
apparent about false negative samples. Other cancers accounted
for 13/135 false positive measures (Table 1). Six of the seven
independently diagnosed non-thoracic malignancies in the KY
cohort measured positively in one or more annual samples. The
single highest value was a subject lost to follow-up after prevalence
screening who was diagnosed with extranodal marginal zone B-
cell lymphoma (MALT) five years after enrollment. Benign
intrathoracic findings were common to subjects with false positive
and true negative measures. The majority of false positives
represented persistent elevations across serial screening cycles.
Among the 130 false positive samples (.640 FU) in subjects with
at least two annual samples, only six (4.6%) were singular events
within the series of two or more annual measures.
Discussion
Primary objectives were to confirm the principles and precepts
of autoantibody profiling and assess the potential of an autoan-
tibody profile to increase efficiency and diagnostic accuracy of
screening CT. Samples from the Mayo Clinic CT screening trial
Autoantibody Profiling for Lung Cancer Screening
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Table 1. Characteristics of cancers associated with the KY screening cohort.
Cancer. Histology Stage
Sample-year
(screening)
Lead time to
diagnosis (months)
Prediction
(,640fu)
Screening-detected Lung Cancers
Prevalence AdenoCa IA 1 0 -
Prevalence AdenoCa IA 1 0 +
Prevalence AdenoCa IA 1 0 +
Incidence Squamous IA 1, 2, 3 24/12/0 +/+/+
Incidence Squamous IIB 1, 2, 3 29/13/0 +/+/+
Clinically-detected Lung Cancers (post-screening)
Incidental Squamous IB 1, 2, 3 41/28/14 +/+/+
Incidental AdenoCa IB 1, 2, 3 45/32/20 –/–/–
Incidental Squamous IB 1, 2, 3 57/44/31 –/–/–
Incidental NSCLC IIIB 1 28 -
Other Cancers*
B-Cell Lymphoma(MALT) Extranodal Marginal Zone
Lymphoma
IIEA 1 59 +
Colon AdenoCa IV 1, 2, 3 50/38/25 +/+/+
Head and Neck Squamous I 1, 2, 3 9/+3/+15 –/+/–
Head and Neck Carcinoma (NOS) IIB 1 31 –
Histocytic Sarcoma (tonsil) Follicular Dendritic Cell
Sarcoma (FDCS)
unknown 1, 2 37/25 +/+
Breast AdenoCa 0 (CIS) 1, 2, 3 53/39/27 +/+/+
Bladder Papillary 0 (CIS) 1, 2, 3 27/15/2 +/+/+
*Exclusion criteria included: (1) Current or prior personal history of lung cancer (2) Prior malignancy except adequately treated non-melanomatous skin cancer or in-situ
cervical cancer.
The table includes class prediction and temporal relationship of sample draw to cancer diagnosis. Binomial prediction is based on additive measures from the six-marker
panel. Up to three individual sample measures from each subject are designated either positive (+) or negative (–) based on levels relative to a predetermined cutoff
value of 640 FU (fluorescent units). Assay results at time-of-diagnosis (radiographic detection) of five screening detected lung cancers (three prevalence and two
incidence cancers) are designated as ‘‘0’’ months. Two samples designated ‘‘+3’’ and ‘‘+15’’ were drawn 3 and 15 months respectively following a diagnosis of a stage I
head and neck cancer in one participant of the lung cancer screening study.
doi:10.1371/journal.pone.0087947.t001
Table 2. Contingency chart: class predictions by sample at various marker levels in the Kentucky screening cohort.
Diagnosis No lung cancer Screening and clinically diagnosed lung cancers
Cutoff Specificity Sensitivity
Absolute
fluorescence By sample (n =237) By case (n=86)
By sample All
cases: (n =19)
By sample
Stage I: (n =5)
By sample
Occult: (n = 14) By case (n =9)
500 31% 22% 58% 80% 50% 56%
600 41% 23% 58% 80% 50% 56%
640 43% 28% 58% 80% 50% 56%
700 48% 38% 53% 80% 50% 56%
800 54% 38% 53% 60% 43% 44%
900 60% 41% 53% 60% 43% 44%
1000 65% 52% 42% 60% 43% 44%
1500 81% 72% 37% 40% 43% 33%
2000 88% 82% 21% 40% 14% 22%
2500 93% 89% 21% 40% 14% 22%
3000 96% 92% 16% 40% 7% 22%
3500 97% 92% 16% 40% 7% 22%
4000 98% 97% 11% 20% 7% 11%
Specificity is presented by case series (all negative measures) and by individual sample (time of negative radiograph). Bolded data are predictions using predetermined
cutoff value (640 FU). Absolute fluorescence is the additive sum of six markers in the panel.
doi:10.1371/journal.pone.0087947.t002
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were used to define range and distribution of a composite measure
within a screening population, and assign a cutoff value that would
allow maximum sensitivity for lung cancers at and below the
detectable limits of CT scanning. Distribution measures and
relative cutoffs for cancer detection were tested in an independent
screening cohort from the 5th district of Kentucky. A cutoff set on
the lower quartile of 180 noncancer controls in the Mayo cohort
provided reliable detection of established stage I cancers and
capacity to detect a percentage of incidence cancers prior to
radiographic appearance in both cohorts. Observed frequency of
serially positive and serially negative values across annual repeats
in the Kentucky screening cohort suggests that autoantibody levels
have a specific biologic basis even when there is no clinically
apparent significance to the measure. The assay does not appear
specific for lung cancer, although the variety of non-thoracic
malignancies precludes any conclusion about histologic specificity.
Inflated cutoff values that resulted from the notable discrepancy
in the quartile distributions between the two cohorts skewed the
dynamic range towards specificity in the Kentucky cohort.
Although demographics, differences in eligibility criteria of the
two studies and numerous independent clinical variables could
account for this discrepancy, neither cohort is adequately sized for
multivariable stratification. Conversely, observed differences in
two independent but uniformly collected, moderately large and
relatively comparable sample sets point strongly to sample age,
processing, handling and/or storage as a source of preclinical
error. Specifically, distribution analysis and assignment of cutoff
values based on archived samples from two high-risk cohorts seems
likely to have identified a biological effect that might not have been
recognized with alternate study designs. Despite the presumption
that autoantibodies are resilient biomarkers, there is a paucity of
data on the consistency of autoantibody measures under various
storage conditions and durations. Albeit limited, literature
indicates serum antibody levels increase in cryopreserved samples
over years of storage, possibly related to antigen-antibody complex
dissociation and protein degradation [19,20]. Importantly, the
current data shows how the validation process can be encumbered
by variables unique to archived sample sets, which must be
considered when transitioning from laboratory-based analysis to
implementation in population-based applications.
Even when given allowance for quantifiable preclinical error
and the effect of inflated cutoff values on predictive accuracy in the
validation set, the data discourage more advanced validation. The
appeal of detecting occult disease with lead-time advantage over
CT scanning is tempered by excessive false negative rates, and
certainly restricts this assay’s utility in selecting individuals that
most warrant serial imaging [5]. Interpretation of positive
measures is further confounded by the apparent lack of specificity
for thoracic malignancy.
Provisional assessment of the small number of radiographically
detectable cancers in post hoc analysis approximates that of
autoantibody profiles independently validated by other groups
testing for established cancers [21–23]. If by extension we assume
the best achievable sensitivity for stage I cancer is 80%, with a
corresponding specificity of 40% expanding our analysis to sample
sets with larger number of established cancers does not seem
warranted. Also similar to other assays in the literature, a
provisional sensitivity of 40% for established disease corresponds
to specificity .90% [21–24]. Adjusting the cutoff for high
specificity seems only to further deviate from a conventional
screening paradigm. If used to further stratify cases by probability
of cancer, however, a cutoff that favors specificity could mitigate
inter-reader variability and reduce the number of false negative
readings on screening CT scans [25,26]. A highly specific assay
might also help discriminate benign from malignant nodules
identified during screening, even though predictive value will be
compromised by the promiscuity of the assay for both occult and
radiographically apparent disease [27]. In summary, this report
does not draw conclusions about future utility of this approach, but
this validation study does not seem to support use of this assay as a
primary population-based screening tool. Combining additional
investigation with knowledge of this assay’s performance may
identify other logical areas for autoantibody profiling in lung
cancer diagnosis and management.
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